Hope for Huntington's: new pill aims to tame harmful proteins
NCT ID NCT07537075
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study tests an oral drug called SKY-0515 in 500 adults with Huntington's disease who have already completed a prior study of the same drug. The goal is to see if the drug can safely lower harmful proteins and improve symptoms over the long term. Participants must be 25 or older and have a genetic confirmation of Huntington's disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON'S DISEASE (HD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Calvary Health Care Bethlehem
Caulfield South, Victoria, 3162, Australia
-
Flinders Medical Centre
Adelaide, South Australia, 5042, Australia
-
Huntington's Disease Association
Auckland, 0604, New Zealand
-
John Hunter Hospital
New Lambton Heights, New South Wales, 2305, Australia
-
New Zealand Brain and Research Institute
Christchurch, 8011, New Zealand
-
The Perron Institute for Neurology and Translational Science (Perron Institute)
Nedlands, Western Australia, 6009, Australia
-
The Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
The University of Queensland
Herston, Queensland, 4006, Australia
-
Wellington Hospital
Wellington, 6021, New Zealand
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.